Abstract 870P
Background
Imaging response to induction chemotherapy (IC) has been used as a chemoradiation (CRT) de-intensification strategy in HPV-related head and neck cancer (HPV-HNC). However, radiographic response can be difficult to interpret and may lag biological response. We evaluate serial cell free HPV DNA (cfHPV DNA) levels during IC and CRT to determine a quantitative measure of early biologic response.
Methods
Patients with locally advanced, HPV-HNC receiving IC with 1-2 cycles of weekly platinum/taxane and definitive CRT were eligible. Peripheral blood was collected biweekly during IC, weekly during CRT, and at 3-4mo follow up visit. cfHPV DNA levels were measured with the Safe-SEQ HPV test from Sysmex Inostics, which is an NGS-based, CLIA-certified assay designed to sensitively detect and quantify HPV16 and HPV18 DNA in plasma.
Results
163 samples across 15 patients completing curative-intent treatment were processed. The primary tumors were oropharyngeal (OPX, n=11), sinonasal/nasopharyngeal (NPX, n=3), and laryngeal (n=1). Median follow up was 13.2 mo. We defined a subset of patients who had ≥95% reduction in baseline cfHPV DNA levels by day 22 of IC as “rapid responders”. This included 4 OPX and 1 NPX patients. All rapid responders had either T4 or N3 disease and three had >15 pack-year smoking history. Mean tumor volume change measured from pre-IC to post-IC CT imaging (median of 43 elapsed days) was a 71% reduction for rapid responders (range: 55% to 89% reduction) and a 32% reduction for non-rapid responders (range: 31% increase to 62% reduction). All rapid responders were alive and locoregionally controlled at 1 year follow up. In contrast, 50% of the non-rapid responders experienced in-field locoregional failure by this time-point, with two dying with disease. Each of the rapid responders completely cleared cfHPV DNA by the end of week 4 of CRT, but one rapid responder rebounded to a low detectable level (1.5 copies/mL) at 3.4mo post-treatment, followed by clinical detection of distant recurrence 10 months later.
Conclusions
cfHPV DNA kinetics after a short course of IC can provide an early, quantitative indication of favorable biology even for clinically high-risk, locally advanced HPV-HNC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sysmex Inostics, Inc. with in-kind support.
Disclosure
Y. Cao: Non-Financial Interests, Non financial benefits, In-kind donation of assay: Sysmex Inostics, Inc. A.P. Kiess: Other, Research Grant: Merck. E. Gramiccioni, D. Schmitt, J. Swindell: Financial Interests, Personal, Full or part-time Employment: Sysmex Inostics, Inc. A. Starus: Financial Interests, Personal, Full or part-time Employment, Sr. Manager, Medical Affairs and Product Development: Sysmex Inostics, Inc. F.S. Jones: Financial Interests, Personal, Full or part-time Employment, Senior Director Medical Affairs & Product Development: Sysmex Inostics, Inc. H. Quon: Financial Interests, Personal, Ownership Interest, Co-Founder, Chief Medical Officer, Stock: Pistevo Decision; Financial Interests, Personal, Advisory Role, Consultant, Stock: Oncospace LLC; Financial Interests, Non financial benefits, In-kind donation of assay: Sysmex Inostics, Inc. T. Seiwert: Financial Interests, Research Funding: Bristol Myers Squibb, AstraZeneca, Genenetch, Cue; Financial Interests, Research Funding, Consultant, Honoraria: Nanobiotix; Financial Interests, Research Funding, Consultant, honoraria: Merck; Non-Financial Interests, Non financial benefits, In-kind donation of assay: Sysmex Inostics, Inc.. All other authors have declared no conflicts of interest.
Resources from the same session
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
919P - A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients
Presenter: Wu xi
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12
921P - HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Presenter: Lisle Nabell
Session: Poster session 12